Please sign in to follow a disease.
New painkiller may reduce nausea after hysterectomy
NCT ID NCT07326683
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new painkiller called tegileridine against the standard drug oxycodone in 68 women recovering from laparoscopic hysterectomy. The main goal was to see which drug caused less nausea and vomiting after surgery. Both drugs were given through an IV, and patients could get extra pain relief if needed. The results could help doctors choose a better option for postoperative pain control.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Tegileridine (a new painkiller) and oxycodone (a standard painkiller)
- What this could lead to
- If tegileridine works better with fewer side effects like nausea, it could offer a new option for managing pain after surgery.
- What could go wrong
- This is a small, single-center study with only 68 participants. The results may not apply to everyone, and tegileridine is still new with unknown long-term risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
68 people
The number who actually took part.
- Started
-
Dec 2025
- Finished
-
Jan 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients undergoing laparoscopic total abdominal hysterectomy with single-lumen endotracheal tube placement under general anaesthesia. 2. Females aged 18-65 years with a BMI of 18-28 kg/m²; 3. Normal mouth opening and head/neck mobility; 4. Preoperative American Society of Anesthesiologists (ASA) physical status classification of I-III and Mallampati airway classification of I or II; 5. Patients must also be scheduled for postoperative analgesia and have signed an informed consent form. Exclusion Criteria: 1. Patients with allergies to the medications used in this study. 2. Patients with severe diseases of major organs, such as the heart, lungs or brain, including a history of acute myocardial infarction, cerebral infarction, asthma or chronic obstructive pulmonary disease; 3. Patients with severe liver or kidney dysfunction, or concomitant severe endocrine disorders such as poorly controlled hypertension, diabetes, hyperthyroidism or hypothyroidism. 4. Patients with a difficult airway, oropharyngeal/cervical anomalies, or a history of prior tracheostomy; 5. A history of prolonged sedative/analgesic use, substance abuse or opioid dependence; 6. Patients with neuropsychiatric disorders or impaired communication/comprehension abilities.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Total laparoscopic hysterectomy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Anesthesiology,the Second Affiliated Hospital of Hainan Medical University
Haikou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.